Kentucky is currently home to 1068 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Louisville, Lexington, Owensboro and Paducah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant
NCT05948540
Recruiting
This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Intervention C - Daridorexant will assess the safety and efficacy of daridorexant in participants with PTSD. Please see NCT05422612 for information on the S-21-02 Master Protocol.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/03/2025
Locations: Cincinnati Veteran's Affairs Medical Center, Fort Thomas, Kentucky
Conditions: Post Traumatic Stress Disorder
Register for Updates
Department of Defense PTSD Adaptive Platform Trial - Master Protocol
NCT05422612
Recruiting
This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Participants are randomized among the multiple cohorts in the study and the resulting randomization enables sharing/pooling of control participants, where all interventions may be compared to a common control (placebo). This master protocol describes the default procedures and analyses for all cohorts;... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/03/2025
Locations: Cincinnati Veteran's Affairs Medical Center, Fort Thomas, Kentucky
Conditions: Post Traumatic Stress Disorder
Register for Updates
Loupe-Based Intraoperative Fluorescence Imaging
NCT04780009
Recruiting
Glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) are the most common primary malignant brain tumors. Survival of patients with these brain tumors is directly related to the extent of resection. Consequently, a great deal of effort has been directed at developing techniques and technologies that allow more extensive, safe resections. This study will test a loupe-based wearable device in the clinical setting and compare its accuracy with a large operative microscope to identify tumor... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/03/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma
Register for Updates
Blood Flow Restriction Training After Patellar INStability
NCT04554212
Recruiting
This research study is designed to allow health care professionals and researchers to answer many questions about whether a new type of physical therapy called blood flow restriction training (called BFRT) will improve recovery for those with patellar instability.
Gender:
ALL
Ages:
Between 14 years and 40 years
Trial Updated:
07/02/2025
Locations: UK Healthcare at Turfland, Lexington, Kentucky
Conditions: Patellar Dislocation, Knee Injuries, Leg Injury, Wounds and Injuries
Register for Updates
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
NCT04365374
Recruiting
This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: University of Louisville, Louisville, Kentucky
Conditions: Brain Metastases
Register for Updates
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
NCT04310020
Recruiting
This phase II trial studies the side effects of radiation therapy followed by atezolizumab in treating patients with stage II or III non-small cell lung cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more cancer cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to g... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Saint Joseph Hospital, Lexington, Kentucky
Conditions: Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Lung Non-Small Cell Carcinoma
Register for Updates
Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
NCT06967389
Recruiting
The goal of this clinical trial is to learn if the drug semaglutide changes markers of disease risk as it relates to weight in children ages 12-15 years old who are obese (class 2 or 3). The main questions it aims to answer are: * How do the rate of weight loss, body mass index (BMI), body composition, heart structure and function, and exercise ability interact with one another in the study population at enrollment? * How do risk markers of disease change over the study in the study participant... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
07/01/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Obesity and Overweight, Obese Adolescents, Weight Management, Weight Loss, Cardiovascular Disease Risk Factor
Register for Updates
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Fort Mitchell, Kentucky
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
ROSE-Longitudinal Assessment With Neuroimaging
NCT05089331
Recruiting
The investigators will perform follow-up on 250 of 500 cases recruited into the ROSE study of cases with deep and lobar intracerebral hemorrhage to perform advanced neuroimaging at 12-24 months post stroke, and evaluations of motor and cognitive function at baseline, 6 months after baseline, and 12 months after baseline to determine predictors of recovery, progressive cognitive or functional impairment. The investigators propose to leverage the recruitment, DNA, RNA-seq and baseline advanced neu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Baptist Health Louisville, Louisville, Kentucky
Conditions: Intracerebral Hemorrhage
Register for Updates
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT04546399
Recruiting
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occu... Read More
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
07/01/2025
Locations: University of Kentucky/Markey Cancer Center, Lexington, Kentucky
Conditions: Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Register for Updates
Genetic and Environmental Risk Factors for Hemorrhagic Stroke
NCT00682695
Recruiting
The purpose of this study is to find risk factors for hemorrhagic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Baptist Health Louisville, Louisville, Kentucky
Conditions: Stroke
Register for Updates
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
NCT06750185
Recruiting
This is a first-in-human (FIH), open-label, multiple-site, dose escalation study which will evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Norton Cancer Institute PARENT, Louisville, Kentucky
Conditions: Advanced Solid Tumor
Register for Updates